Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01633970 · ClinicalTrials.gov registry record · Phase 1
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Cancer, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 11
- Study locations
NCT01633970: Completed Phase 1 study of Cancer, sponsored by Genentech.
NCT01633970 is a Phase 1 study of Cancer that has completed, run by Genentech. The registered enrollment target is 240 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (93% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01633970, a Phase 1 study of Cancer, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 11
- Study locations
Study Summary
This open-label, Phase Ib study that has six treatment arms is designed to assess the safety, pharmacology and preliminary efficacy of atezolizumab (MPDL3280A; an engineered anti-programmed death-ligand 1 \[PDL1\] antibody) administered with bevacizumab (Arm A) and with bevacizumab plus oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (FOLFOX) (Arm B), with carboplatin and paclitaxel (Arm C), with carboplatin and pemetrexed (Arm D), with carboplatin and nab-paclitaxel (Arm E), and with nab-paclitaxel (Arm F) in participants with locally advanced or metastatic solid tumors. The study includes dose escalation cohort for establishing the maximum tolerated dose (MTD) or maximum administered dose (MAD) and then expansion cohort will be initiated based on a selected dose level at or below the MTD or MAD.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Leucovorin
- DRUG 5-FU
Study Locations (11)
Massachusetts
- Massachusetts General Hospital. - Boston
- Beth Israel Deaconess Med Ctr - Boston
- Dana Farber Can Ins - Boston
North Carolina
- Duke University Medical Center - Durham
- Carolina BioOncology Institute; Can Therapy & Res Ctr - Huntersville
Colorado
- University of Colorado Cancer Center - Aurora
Connecticut
- Yale University - New Haven
District of Columbia
- Georgetown University Medical Center Lombardi Cancer Center - Washington D.C.
Illinois
- Uni of Chicago - Chicago
New York
- Laura and ISAAC Perlmutter Cancer Center at NYU Langone. - New York
Tennessee
- Sarah Cannon Research Inst. - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2012-07-11 |
| Est. Completion | 2020-02-26 |
| Phase | Phase 1 |
What the finished NCT01633970 record still lists
NCT01633970 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT01633970 lists 11 locations in 8 states (Massachusetts, North Carolina, Colorado).
Frequently Asked Questions
What is clinical trial NCT01633970 about?
NCT01633970 is a clinical study titled "A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors". This open-label, Phase Ib study that has six treatment arms is designed to assess the safety, pharmacology and preliminary efficacy of atezolizumab (MPDL3280A; an engineered anti-programmed death-ligand 1 \[PDL1\] antibody) administered with bevacizumab (Arm A) and with bevacizumab plus oxaliplatin,...
What is the current status of trial NCT01633970?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2012-07-11. Estimated completion is 2020-02-26.
What conditions does trial NCT01633970 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT01633970?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Atezolizumab (DRUG), Leucovorin (DRUG), 5-FU (DRUG).
Who is sponsoring clinical trial NCT01633970?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01633970 being conducted?
This trial has 11 study locations across Colorado, Connecticut, District of Columbia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01633970's enrollment target sits among peer trials
240 211th of 615 higher than 400 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI